» Articles » PMID: 32648679

The Nose-To-Brain Transport of Polymeric Nanoparticles Is Mediated by Immune Sentinels and Not by Olfactory Sensory Neurons

Overview
Journal Adv Biosyst
Date 2020 Jul 11
PMID 32648679
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The nose-to-brain (N-to-B) transport mechanism of nanoparticles through the olfactory epithelium (OE) is not fully understood. Most research utilized nasal epithelial cell models completely deprived of olfactory cells. Aiming to shed light into key cellular pathways, in this work, for the first time, the interaction of polymeric nanoparticles in a 17-483 nm size range and with neutral and negatively and positively charged surfaces with primary olfactory sensory neurons, cortical neurons, and microglia isolated from olfactory bulb (OB), OE, and cortex of newborn rats is investigated. After demonstrating the good cell compatibility of the different nanoparticles, the nanoparticle uptake by confocal laser scanning fluorescence microscopy is monitored. Our findings reveal that neither olfactory nor forebrain neurons internalize nanoparticles. Conversely, it is demonstrated that olfactory and cortical microglia phagocytose the nanoparticles independently of their features. Overall, our findings represent the first unambiguous evidence of the possible involvement of microglia in N-to-B nanoparticle transport and the unlikely involvement of neurons. Furthermore, this approach emerges as a completely new experimental tool to screen the biocompatibility, uptake, and transport of nanomaterials by key cellular players of the N-to-B pathway in nanosafety and nanotoxicology and nanomedicine.

Citing Articles

Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders.

Awad R, Avital A, Sosnik A Acta Pharm Sin B. 2023; 13(5):1866-1886.

PMID: 37250152 PMC: 10213616. DOI: 10.1016/j.apsb.2022.07.003.


Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs.

Lofts A, Abu-Hijleh F, Rigg N, Mishra R, Hoare T CNS Drugs. 2022; 36(7):739-770.

PMID: 35759210 PMC: 9243954. DOI: 10.1007/s40263-022-00930-4.


Advances in Non-Animal Testing Approaches towards Accelerated Clinical Translation of Novel Nanotheranostic Therapeutics for Central Nervous System Disorders.

Lynch M, Gobbo O Nanomaterials (Basel). 2021; 11(10).

PMID: 34685073 PMC: 8538557. DOI: 10.3390/nano11102632.


Heterocellular spheroids of the neurovascular blood-brain barrier as a platform for personalized nanoneuromedicine.

Kumarasamy M, Sosnik A iScience. 2021; 24(3):102183.

PMID: 33718835 PMC: 7921813. DOI: 10.1016/j.isci.2021.102183.


Mixed Amphiphilic Polymeric Nanoparticles of Chitosan, Poly(vinyl alcohol) and Poly(methyl methacrylate) for Intranasal Drug Delivery: A Preliminary In Vivo Study.

Schlachet I, Moshe Halamish H, Sosnik A Molecules. 2020; 25(19).

PMID: 33008001 PMC: 7582691. DOI: 10.3390/molecules25194496.